c-Met targeted therapy of cholangiocarcinoma

Matei P. Socoteanu, Frank Mott, Gianfranco Alpini, Arthur E. Frankel

Research output: Contribution to journalReview article

24 Scopus citations

Abstract

Cholangiocarcinoma continues to be a challenging (disease to treat. Systemic therapy is used in unresectable disease, disease progression after surgery, and in the palliative setting. Unfortunately, results of multiple phase H trials have rarely yielded positive results. As data on the molecular carcinogenesis of cholangiocarcinoma is developing, we are more able to understand the disease process and can use this understanding to create unique targeted therapies. We reviewed the role of c-Met/hepatocyte growth factor (HGF) in the development of cholangiocarcinoma. Furthermore, we explored the use of the c-Met guided cascade as a target to treat cholangiocarcinoma. We reviewed the current use and options for future development of c-Met agents to treat this disease.

Original languageEnglish (US)
Pages (from-to)2990-2994
Number of pages5
JournalWorld Journal of Gastroenterology
Volume14
Issue number19
DOIs
Publication statusPublished - May 21 2008

    Fingerprint

Keywords

  • Chemotherapy
  • Cholangiocarcinoma
  • Target therapy
  • c-Met

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Socoteanu, M. P., Mott, F., Alpini, G., & Frankel, A. E. (2008). c-Met targeted therapy of cholangiocarcinoma. World Journal of Gastroenterology, 14(19), 2990-2994. https://doi.org/10.3748/wjg.14.2990